Solid Tumor Testing Market Overview:
Solid Tumor Testing Market valued at USD 29.00 billion in 2024, is projected to grow to USD 45.88 billion by 2032, achieving a steady CAGR of 5.9%. Escalating cancer incidence, advancements in next-generation sequencing, and the rise of personalized medicine are driving demand for comprehensive genomic profiling, with North America dominating through sophisticated healthcare infrastructure and rapid adoption of liquid biopsy technologies.
Key Highlights & Insights
Market Size & Growth: From USD 29.00 billion in 2024 to USD 45.88 billion by 2032, exhibiting a CAGR of 5.9%.
Dominating Region: North America holds over 40% market share, propelled by high cancer prevalence, extensive reimbursement coverage, and leadership in NGS-based companion diagnostics for targeted therapies.
Leading Segment: Breast cancer testing commands 25.9% market share, driven by widespread screening programs, HER2/BRCA mutations, and demand for hormone receptor profiling in early-stage detection.
Key Driver: Surge in precision oncology requiring tumor profiling for immunotherapy selection, coupled with minimally invasive liquid biopsies enabling real-time monitoring and treatment optimization.
► Get a sample of the report:https://www.maximizemarketresearch.com/request-sample/167421/
Recent Developments
2024-2025: Guardant Health (U.S.) launched Shield blood test for colorectal cancer screening, gaining FDA breakthrough status for early detection.
November 2025: Foundation Medicine (U.S.) expanded FoundationOne CDx approvals for lung cancer companion diagnostics, partnering with Roche for pan-tumor profiling.
2025: Tempus (U.S.) introduced AI-driven solid tumor panels integrating multi-omics data, while Illumina (U.S.) rolled out TruSight Oncology 500 for comprehensive NGS testing.
Global collaborations accelerate ctDNA-based monitoring for treatment response.
FAQs:
What is solid tumor testing? Genomic/proteomic analysis identifying mutations, biomarkers for diagnosis, prognosis, and therapy selection.
Why North America dominates? Advanced diagnostics infrastructure and 50%+ reimbursement for NGS testing.
Key cancer types? Breast (largest), lung, colorectal, prostate.
Main technologies? NGS (fastest-growing), IHC, FISH.
Future outlook? Liquid biopsy to capture 30% market by 2030.
Market Dynamics
Growth Drivers:
Cancer incidence rising 2-3% annually, demanding early molecular detection.
Targeted therapies/immunotherapies require biomarker identification via NGS.
Shift to liquid biopsies reduces invasive biopsies by 70%.
Regulatory approvals for companion diagnostics expand test indications.
Challenges:
High NGS costs limiting access in emerging markets.
Reimbursement variability across payers and regions.
Data privacy concerns with genomic information sharing.
Opportunities:
AI/ML integration for variant interpretation and prediction.
Expansion into rare tumors and pediatric oncology.
Companion diagnostics for novel ADCs and bispecific antibodies.
Regional Analysis
North America: Market leader with U.S. dominance in innovation and reimbursement.
Europe: Strong growth via UK’s NHS Genomic Medicine and Germany’s precision oncology programs.
Asia Pacific: Fastest-growing with China’s cancer screening initiatives and Japan’s NGS adoption.
Latin America, Middle East & Africa: Emerging demand from expanding private diagnostics.
Product Segmentation
By Type: Genetic Testing (dominant), Conventional Testing.
By Cancer Type: Breast Cancer (largest), Lung, Colorectal, Prostate, Melanoma, Others.
By Application: Clinical Diagnostics (65% share), Research.
By Technology: NGS, IHC, FISH, PCR, Others.
By End-User: Hospitals (leading), Diagnostic Labs, Cancer Research Institutes.
Key Trends
Liquid biopsy dominance with ctDNA for monitoring MRD and resistance.
Multi-omic panels combining DNA/RNA/proteins for comprehensive profiling.
AI-powered variant classification reducing TAT from weeks to days.
Decentralized testing via CLIA-certified labs near patients.
HRD testing for PARP inhibitor patient selection.
Conclusion
The solid tumor testing market is the cornerstone of modern oncology, translating genomic complexity into actionable treatment decisions. North America’s innovation ecosystem accelerates global adoption, ensuring patients receive biomarker-matched therapies that improve survival and quality of life through 2032 and beyond.
◉ Get Market Research Latest Trends
♦ Construction Smart Wearable Market
♦ Maximize Market Research is launching a subscription model for data and analysis in the MMR Statistics
Contact Maximize Market Research:
3rd Floor, Navale IT Park, Phase 2
Pune Bangalore Highway, Narhe,
Pune, Maharashtra 411041, India
[email protected]
+91 96071 95908, +91 9607365656
About Maximize Market Research:
Maximize Market Research is a multifaceted market research and consulting company with professionals from several industries. Some of the industries we cover include medical devices, pharmaceutical manufacturers, science and engineering, electronic components, industrial equipment, technology and communication, cars and automobiles, chemical products and substances, general merchandise, beverages, personal care, and automated systems. To mention a few, we provide market-verified industry estimations, technical trend analysis, crucial market research, strategic advice, competition analysis, production and demand analysis, and client impact studies.
